Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;20(6):622-634.
doi: 10.6004/jnccn.2022.0031.

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

William G Wierda  1 , Jennifer Brown  2 , Jeremy S Abramson  3 , Farrukh Awan  4 , Syed F Bilgrami  5 , Greg Bociek  6 , Danielle Brander  7 , Asher A Chanan-Khan  8 , Steve E Coutre  9 , Randall S Davis  10 , Herbert Eradat  11 , Christopher D Fletcher  12 , Sameh Gaballa  13 , Armin Ghobadi  14 , Muhammad Saad Hamid  15 , Francisco Hernandez-Ilizaliturri  16 , Brian Hill  17 , Paul Kaesberg  18 , Manali Kamdar  19 , Lawrence D Kaplan  20 , Nadia Khan  21 , Thomas J Kipps  22 , Shuo Ma  23 , Anthony Mato  24 , Claudio Mosse  25 , Stephen Schuster  26 , Tanya Siddiqi  27 , Deborah M Stephens  28 , Chaitra Ujjani  29 , Nina Wagner-Johnston  30 , Jennifer A Woyach  31 , J Christine Ye  32 , Mary A Dwyer  33 , Hema Sundar  33
Affiliations

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

William G Wierda et al. J Natl Compr Canc Netw. 2022 Jun.

Abstract

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources